2024 AFS meeting showcased Implantica AG's RefluxStop® implant, targeting FDA approval for GERD treatment.
Implantica AG's RefluxStop® implant gained significant attention at the 2024 American Foregut Society (AFS) meeting in Colorado, where over 600 experts discussed innovations in foregut disease treatments. The company is pursuing FDA approval for RefluxStop®, which aims to address gastroesophageal reflux disease (GERD) for millions of Americans. Positive long-term and real-world data were presented, highlighting the product's potential to improve GERD management.
October 10, 2024
3 Articles